European journal of clinical investigation
-
Eur. J. Clin. Invest. · Aug 2014
FGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cells.
Fibroblast growth factor (FGF)-23 is a key regulator of phosphate homeostasis. Higher FGF-23 levels are correlated with poor outcomes in cardiovascular diseases. FGF-23 can produce cardiac hypertrophy and increase intracellular calcium, which can change cardiac electrical activity. However, it is not clear whether FGF-23 possesses arrhythmogenic potential through calcium dysregulation. Therefore, the purposes of this study were to evaluate the electrophysiological effects of FGF-23 and identify the underlying mechanisms. ⋯ FGF-23 increases HL-1 cells arrhythmogenesis with calcium dysregulation through modulating calcium-handling proteins.
-
Eur. J. Clin. Invest. · Aug 2014
Treatment with human insulin does not increase thyroid cancer risk in patients with type 2 diabetes.
Whether human insulin therapy may increase thyroid cancer risk in patients with type 2 diabetes mellitus (T2DM) has not been investigated. ⋯ This study does not support the role of human insulin therapy in increasing the risk of thyroid cancer in patients with T2DM.
-
Eur. J. Clin. Invest. · Aug 2014
Comparative StudyMeasurement of rivaroxaban and apixaban in serum samples of patients.
The determination of rivaroxaban and apixaban from serum samples of patients may be beneficial in specific clinical situations when additional blood sampling for plasma and thus the determination of factor Xa activity is not feasible or results are not plausible. ⋯ The results indicate that rivaroxaban and apixaban concentrations can be determined specifically from serum samples.